% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Maurus:178088,
      author       = {J. Maurus and T. Terzer$^*$ and A. Benner$^*$ and S.
                      Goisser and A. Eidam and A. Roth and M. Janssen and S.
                      Jaramillo and H. M. Lorenz and W. Micol and K. Hauer and C.
                      Müller-Tidow and J. M. Bauer and K. Jordan and N. R.
                      Neuendorff},
      title        = {{V}alidation of a proxy-reported {SARC}-{F} questionnaire
                      for current and retrospective screening of
                      sarcopenia-related functional impairments.},
      journal      = {Journal of cachexia, sarcopenia and muscle},
      volume       = {13},
      number       = {1},
      issn         = {2190-5991},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2021-03095},
      pages        = {264-275},
      year         = {2022},
      note         = {Volume13, Issue1, February 2022, Pages 264-275},
      abstract     = {The strength, assistance walking, rise from a chair, climb
                      stairs, and falls (SARC-F) questionnaire is a
                      well-established instrument for screening of sarcopenia and
                      sarcopenia-related functional impairments. As it is based on
                      self-reporting, its use precludes patients who are unable to
                      answer the questionnaire as a consequence of severe acute
                      diseases or cognitive impairment. Therefore, we aimed to
                      validate a proxy-reported version of the SARC-F for both
                      ad-hoc as well as retrospective screening for severe
                      sarcopenia-related functional impairments.Patients aged
                      ≥60 years completed the SARC-F and performed the short
                      physical performance battery (SPPB) at baseline (T1).
                      Proxies in Cohort A gave a simultaneous assessment of the
                      patients' functional status with the proxy-reported SARC-F
                      at T1 and again, retrospectively, after 3 months (T2).
                      Proxies in Cohort B only completed the SARC-F
                      retrospectively at T2. The questionnaires' performances were
                      assessed through sensitivity/specificity analyses and
                      receiver operating characteristic (ROC) curves. For
                      non-inferiority analyses, results of both the
                      patient-reported and proxy-reported SARC-F were correlated
                      with the SPPB total score as well as the results of the
                      chair-rise test subcategory; the respective correlation
                      coefficients were tested against each other.One hundred and
                      four patients and 135 proxies participated. Using a SPPB
                      score < 9 points as the reference standard, the
                      proxy-reported SARC-F identified patients at high risk for
                      sarcopenia-related functional impairment with a sensitivity
                      of 0.81 (ad-hoc), 0.88 (retrospective Cohort A), and 0.87
                      (retrospective Cohort B) as well as a specificity of 0.89
                      (ad-hoc), 0.78 (retrospective Cohort A), and 0.64
                      (retrospective Cohort B). Areas under the ROC curves
                      were ≥ 0.9 for the ad-hoc proxy-reported SARC-F and the
                      retrospective proxy-reported SARC-F in both cohorts. The
                      proxy-reported SARC-F showed a non-inferior correlation with
                      the SPPB compared with the patient-reported SARC-F for
                      ad-hoc (P = <0.001) as well as retrospective screening for
                      severe sarcopenia-related functional impairment in both
                      Cohorts A (P = 0.007) and B (P = 0.026).Proxy-reported
                      SARC-F is a valid instrument for both ad-hoc as well as
                      retrospective screening for sarcopenia-related functional
                      impairment and could become the standard tool for evaluating
                      this risk in older adults with severe acute disease, for
                      example, in patients with quickly evolving haematological
                      conditions.},
      keywords     = {Patient-reported outcome (Other) / Premorbid condition
                      (Other) / Proxy-reported outcome (Other) / SARC-F (Other) /
                      Sarcopenia (Other) / Sarcopenia-related functional
                      impairments (Other)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34898035},
      doi          = {10.1002/jcsm.12871},
      url          = {https://inrepo02.dkfz.de/record/178088},
}